

**Title: Consensus guideline for the management of patients with appendiceal tumors**

**Part 1: Appendiceal tumors without peritoneal involvement**

**Authors: PSM Appendiceal Tumor Writing Group, PSM Consortium Group**

**Correspondence:**

Kiran K. Turaga, MD, MPH, FACS  
Division Chief of Surgical Oncology  
Yale School of Medicine  
330 Cedar St, FMB130J  
New Haven, CT, 06511, USA

## **Abstract**

### Background:

Appendiceal tumors comprise a heterogeneous group of tumors which may be localized or disseminate throughout the peritoneum. Limited high quality clinical data exists and many practices have been extrapolated from colorectal cancer without validation in appendiceal cohorts. Many controversies exist regarding their treatment, and practices vary widely between centers and care settings. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care.

### Methods

The 2018 Chicago consensus guideline was updated via modified Delphi consensus, performed over two rounds using nationally circulated surveys. Supporting evidence was evaluated using rapid systematic reviews. Key systemic therapy concepts were summarized by content experts.

### Results

Most supporting literature consists of observational studies, but increasingly high-quality studies are becoming available to drive management. Two consensus-based pathways were generated for localized appendiceal tumors, one for epithelial mucinous neoplasms and another for appendiceal adenocarcinoma. Of 138 participants responding in the first round, 133 (96%) engaged in the second round. Over 90% consensus was achieved for all pathway blocks. Key points include minimizing intervention invasiveness where permitted by pathologic classification and margin status, and determining what margin and pathologic findings are indications for consideration of cytoreduction with or without intraperitoneal chemotherapy. Surveillance and systemic therapy recommendations are also presented.

### Conclusion

With growing but still primarily observational evidence currently dictating care, these consensus recommendations provide expert guidance in the treatment of appendiceal tumors without peritoneal involvement.

## **BACKGROUND**

Appendiceal tumors comprise a diverse group of pathologies of the vermiform appendix. Their incidence has been markedly increasing, doubling in the years 2004-2017 alone; recent estimates report 0.97 cases per 100,000 individuals.<sup>1,2,3</sup> Although still a rare disease, it is critical for general surgeons to be familiar with appendix tumors because of the substantially higher incidence of 1-3% in those undergoing appendectomy, and for primary and emergency care generalists to avoid missed diagnoses.<sup>4-7</sup> Complicated appendicitis, including perforation or abscess, is associated with greater risk of a neoplastic diagnosis, with rates ranging from 5-29%.<sup>5,8-12</sup>

Mucinous neoplasms represent over half of appendix tumors; the rest are predominantly epithelial (65-70%) followed by neuroendocrine (~20%).<sup>13</sup> The most common epithelial malignancies are mucinous adenocarcinoma (35-40%), followed by colonic/intestinal type (7-27%), goblet cell (about 20%), and signet ring adenocarcinoma (estimates usually under 10%).<sup>1,14,15</sup> Approximately 40-50% of appendix tumors present with distant disease at diagnosis, usually peritoneal.<sup>3,14,16-19</sup>

Prognosis varies widely across disease histology and stage. Low grade neuroendocrine tumors, not addressed by this guideline, have the best prognosis; of non-metastatic epithelial tumors, the most recent studies report five-year overall survival of 63-75% for well- and moderately- differentiated mucinous disease, and 60-70% for non-mucinous.<sup>1,3,14,17,18,20-23</sup> Data on non-metastatic, higher-grade tumors is scant as they often present at more advanced stages.

Given the rarity of appendiceal tumors, prospective studies are challenging and randomized studies are nearly non-existent, so data to guide their management are low-quality and there are no well-established standards of care.<sup>24,25</sup> To fill this need, the multidisciplinary Chicago Consensus Working Group was formed in 2018 to generate consensus recommendations for peritoneal malignancies including appendix tumors.<sup>26</sup> Herein, these recommendations are updated by expert consensus for the clinical management of patients with localized appendiceal mucinous neoplasms and localized appendiceal adenocarcinoma, supported with recent evidence synthesized through rapid systematic reviews.

### **Conceptual Overview and Changes from the 2018 Chicago Consensus<sup>26</sup>**

Peritoneal disease has been removed from the pathology-defined localized pathways and reorganized as a unified treatment pathway, which will be addressed in a separate document. All pathways feature a more comprehensive, multidisciplinary initial evaluation recommendation. Pathways have been streamlined to emphasize preferred treatment options. Surveillance recommendations have been unified across pathways. Finally, systemic chemotherapy tables have been developed to describe prevailing trends in systemic treatment.

## **METHODS**

The methods for the 2023 consensus update of the 2018 Chicago Consensus Guidelines have been described in detail in a separate manuscript.<sup>27</sup> Major components are presented below.

### **Consensus Group Structure**

The Appendiceal Tumor Working Group included fifteen multidisciplinary experts. Two steering committee core members coordinated the effort and prepared all revisions (FM,

EG). Sixteen trainees (medical students, residents, and fellows) conducted the rapid reviews.

### **Modified Delphi Process**

The original Chicago Consensus guidelines were reviewed by the Appendiceal Tumor Working Group and Consortium leadership to align with evidence published since the last consensus. Recommendations were revised using two rounds of modified Delphi consensus across the Consortium by soliciting degrees of agreement with each recommendation on a five-point Likert scale via Qualtrics survey. A threshold of 75% was set for inclusion of a guideline, with revision required below and considered above 90% consensus to improve agreement.

### **Rapid Review of the Literature**

Rapid systematic reviews were performed of Pubmed indexed literature in Medline in three key areas, developed in conjunction with a medical librarian specialist. The search period ranged up to August 2023. The search strategies and study protocol were registered with the international prospective register of systematic reviews (PROSPERO) and therefore will not be replicated here. The search strategy may be reviewed in the supplement (Supplemental Table 1).

The following key review question is addressed in this document:

1. In patients with moderate to poorly differentiated appendiceal adenocarcinoma undergoing cytoreductive surgery, which systemic therapy sequences and regimens are associated with superior survival and safety outcomes (total neoadjuvant, perioperative, adjuvant alone)? (PROSPERO CRD42023463216)

The other two key questions will be discussed in the part 2 appendiceal tumor guidelines with the accompanying peritoneal disease pathway.

Reviews were conducted and data extracted according to the published review methodology with minimal changes. Further criteria emerging from screening may be reviewed in the supplement (Supplemental Table 2). As no randomized trials were eligible for inclusion, quality analysis utilized the Newcastle Ottawa framework, which allots up to nine stars for methodologic quality, with six or higher considered good-quality.<sup>28,29</sup> Abstract and full text screening was performed in duplicate, and extraction and quality analysis was performed individually with secondary verification.

The systemic chemotherapy table presented herein was drafted collaboratively by the Appendiceal Tumor Working Group, with directed guidance from medical oncologist contributors. It was then circulated for feedback from the consortium group alongside the Delphi round 2 consensus survey.

## **RESULTS**

### **Pathways**


Of 138 experts who voted on the clinical pathways for appendiceal mucinous neoplasms (AMN) and appendiceal adenocarcinoma in the first round, 133 (96%) participated in the second round. The group comprised 92 (67%) surgical oncologists, 20 (16%) medical oncologists, 12 (12%) pathologists, and 5 (5%) experts from other disciplines. This pathway was divided into eleven main blocks. After two Delphi rounds, the blocks are summarized below with supporting literature incorporated where appropriate.

## **Rapid review**

A total of 1179 abstracts were screened; 247 were included for full-text review and a total of 34 were selected for inclusion in the review, reporting outcomes specific to patients with peritoneal metastases of moderate- and poorly-differentiated appendiceal origin undergoing cytoreductive surgery and systemic chemotherapy. Exclusions are quantified in the PRISMA flow diagram (Figure 1) and further described in Supplemental Table 2.

Outcomes were overall and disease-free survival, and adverse events. Seventeen studies reported on preoperative or neoadjuvant chemotherapy (<sup>30-46</sup>), 6 reported on postoperative or adjuvant chemotherapy (<sup>47-51</sup>), 9 reported on both (<sup>52-60</sup>), and 2 reported on other or unspecified regimens (<sup>61,62</sup>). These studies are summarized in Table 2, addressed qualitatively in Principles of Systemic Therapy, and applied in blocks 3 and 6 of the Appendiceal Adenocarcinoma pathway. Quality assessment can be found in Supplemental Table 3.

**Figure 1. PRISMA Diagram**



## **PRINCIPLES OF SYSTEMIC THERAPY**

One of the key current issues in appendix tumors is the role, regimen, and timing of systemic chemotherapy, which is currently influenced by a combination of the few small single prospective or retrospective studies in appendix tumors, and larger trials in colorectal cancer, despite increasing evidence that appendix cancer has a distinct biology from colorectal cancer.<sup>63–67</sup> In addition to the lack of high-quality evidence, low-grade lesions are also likely resistant to systemic chemotherapy, confounding the results of prior studies and limiting the applicability of their conclusions.<sup>68</sup>

### **Cytotoxic chemotherapy for localized appendix tumors**

Localized appendix tumors may include WHO grade 1 primaries, either low-grade appendiceal mucinous lesions or well-differentiated adenocarcinoma. High-grade appendiceal mucinous neoplasms most likely should be treated similarly. At present, available studies indicate no benefit from the use of 5-FU based chemotherapy in this population, so it is not recommended.<sup>24,53,69–71</sup>

When the primary lesion is an adenocarcinoma with high-risk features without peritoneal involvement, up-front resection with consideration of adjuvant chemotherapy is preferred by expert consensus. High risk features have largely been extrapolated from colorectal cancer literature without validation in appendiceal cohorts, including T4 tumor size, invasion of adjacent structures, inadequate lymph node yield, and tumor perforation. High-risk features validated in appendiceal malignancy include lymph node involvement, signet ring cells, and less differentiated or non-mucinous histology.<sup>52,54,71–77</sup>

The rationale for this is partly mechanistic, as tumors with poor biology are anticipated to have higher likelihood of distant spread. Limited observational evidence has shown benefit associated with the use of adjuvant chemotherapy in node-positive, high-grade, and/or non-mucinous disease.<sup>48,53,54,59,60,71–73,78</sup> Other studies have shown minimal benefit or even detriment after adjuvant therapy; it is unclear how much of this variation reflects selection bias, as the patients who are most likely to undergo adjuvant therapy are those who are well enough to do so.<sup>47,49,51,52,56</sup> To our knowledge, no studies have comprehensively evaluated the role of modern neoadjuvant therapy for resectable appendix tumors without peritoneal involvement; at present expert consensus opinion is not in favor of neoadjuvant therapy in that setting, as it would delay definitive resection.

### **Cytotoxic chemotherapy for tumors with peritoneal disease**

Pathologic grade typically dictates the role of chemotherapy in appendix tumors with peritoneal spread. If both the primary tumor and associated peritoneal lesions are low-grade, cytotoxic therapies are usually not indicated. When resectable, definitive resection should be pursued. When not resectable, palliative debulking may be considered. Cytotoxic systemic therapies may be a part of clinical trials or in care pathways focused on symptom control, but no evidence currently supports their use for improved disease control or survival. If the peritoneal disease is low-grade but the primary is found to have high-risk features, as above, adjuvant chemotherapy should be considered as for any high-grade primary.

For appendiceal tumors with high-grade peritoneal disease histology, the grade of the primary does not affect management; even where there is substantial discordance, such as a LAMN or well-differentiated adenocarcinoma (which would be vanishingly rare), the peritoneal pathology guides management. Some studies suggest some degree of disease response with systemic chemotherapy, with disease stability or improvement on imaging in

20-75% of patients, and some patients with unresectable disease becoming eligible for cytoreduction.<sup>79–82</sup> In one prospective trial, 50% of 34 patients receiving preoperative chemotherapy had disease stability or response on imaging, confirmed by intraoperative findings, and of those 17, 53% (9 of the 17) had lower tumor grade on pathology than in samples from prior chemotherapy.<sup>32</sup> A subset of observational studies support modest disease control or response and increased survival after preoperative chemotherapy.<sup>31–34,37,39,61</sup>

However, this may not translate to cohort-wide overall-, recurrence-free, or progression-free survival, as a number of observational studies suggest a lack of benefit of preoperative chemotherapy in one or all of those domains.<sup>31,33,34,36,41,42,44,47,50,52,54,56,57,83</sup> Overall and disease-free survival is still poor even with definitive cytoreduction; a large study of the US HIPEC collaborative estimates 23.2% five-year disease-free survival and 43.8% overall survival for high-grade appendiceal tumors with peritoneal involvement.<sup>84</sup> Some studies show a survival benefit from postoperative therapy as well, but there is conflicting data regarding its role or benefit.<sup>48,52,53</sup> This observation suggests that disease-specific underlying features which are poorly understood may be driving these treatment outcomes. Further research in this area may allow for directed management.

Weighing the existing evidence summarized above and in Table 2, which summarizes all studies included in the key question 1 rapid review, the expert consensus recommendation of the Peritoneal Surface Malignancy Consortium is to administer chemotherapy prior to attempting cytoreduction, or as definitive therapy if cytoreduction is not feasible, for high-grade peritoneal malignancy of appendiceal origin. When complete cytoreduction is predicted, systemic chemotherapy is useful for assessing disease biology and response, and when incomplete cytoreduction is predicted (high PCI or other anatomic factors), it is recommended as conversion therapy. If cytoreduction is incomplete or if the preoperative regimen was incomplete, postoperative chemotherapy should be considered. There is no clear consensus on regimen timing; when studied, perioperative regimens have been shown to potentially be more challenging for patients to complete than total preoperative, but may be worth considering, particularly when surgery must be expedited.<sup>85</sup>

### **Cytotoxic chemotherapy regimens**

Systemic chemotherapy for appendiceal malignancy commonly relies on the intravenous 5-fluorouracil backbone, or less commonly oral capecitabine, typically used in colorectal cancers. Regimens are typically either doublet, with oxaliplatin or irinotecan as the second agent, or triplet, with both; in patients unable to tolerate doublet or triplet chemotherapy, singlet may be employed.<sup>35,37–39,46,48,53,57,73,81,86,87</sup> At this time only small retrospective studies have been done, so there is no clear evidence suggesting better outcomes with either regimen, but there is higher toxicity with triplet regimens, mandating careful patient selection.<sup>38</sup> Most therapeutic regimens paired with definitive surgical management, whether pre-, peri-, or postoperative, are intended for a 3-6 month duration, but if definitive surgical management is not feasible, cytotoxic chemotherapy may be part of a long-term management strategy. Re-evaluation is generally performed every three months when intended to query disease biology or attempt conversion to resectable disease.<sup>26,32,57</sup>

### **Appendix tumor genetics and targeted and molecular therapies**

The role of targeted and molecular therapies is not well-defined in appendix tumors and is still largely extrapolated from colorectal and other GI cancers, but recent studies have explored genetic profiles of appendiceal tumors in the hopes of identifying effective targets.



Four of the most common mutations in appendix cancer are KRAS (>70%), GNAS (50-70%), TP53 (up to 40%), and APC (up to 20%). The relative frequency of these mutations is distinct from that of colorectal cancer, particularly in the paucity of APC and TP53 mutations compared to 70-80% of colorectal cancers. High microsatellite-instability and MMR-deficiency are relatively uncommon in appendix cancer (6%) as well.<sup>65-67,88,89</sup>

As with most solid tumors, all patients with metastatic disease should receive next generation sequencing for molecular profiling with an accepted next generation sequencing panel to identify potential molecular targets. Retrospective data suggests that molecular information may also inform prognosis and/or predict therapy response, although targeted randomized studies in appendiceal cancer have not been performed.<sup>64,65</sup> When possible, tissue should be sent for tumor molecular profiling; circulating (blood) profiling may not be as sensitive.<sup>90</sup>

Germline variants, including those associated with hereditary cancer syndromes, have been detected at frequencies approaching 10-12% in patients with appendiceal tumors, although these variants may be incidental to disease biology and the relevance to therapeutic management is unknown.<sup>89,90</sup> Testing for germline variants may be considered, taking into account the individual's family history of cancer.

One molecularly-targeted treatment that may be applicable to metastatic appendiceal cancer is anti-VEGF agents, most commonly bevacizumab, which has been associated with improved outcomes in some observational studies.<sup>87</sup> Anti-VEGF therapy may be considered in most settings in which systemic therapy is considered, with preference to those in which no resection or incomplete resection has taken place, although they should be avoided in patients assessed to be at risk of impending bowel obstruction or perforation, bleeding, or arterial thrombosis. Anti-EGFR agents have a more controversial role, as they have unclear survival benefit in appendix cancer and studies have raised concern for worse survival in patients with RAS mutations.<sup>87,88</sup>

Possible therapeutic options for less common mutations may be extrapolated from other cancers. The NCCN guidelines for appendix cancer at time of writing are presented alongside colorectal cancer recommendations and recommend similar use of targeted therapies for druggable targets in late, previously treated, and/or metastatic settings, such as treating BRAF V600E mutated tumors with combination anti-EGFR and anti-BRAF agents.<sup>91</sup> Deficient MMR and MSI-H lesions may be treated with anti-PD1 or combination anti-PD1 and anti-CTLA4 therapy.<sup>91</sup> A recent trial investigated the effect of combination anti-PD1 (atezolizumab) and anti-VEGF (bevacizumab) therapy in 16 individuals with unresectable, predominantly low-grade mucinous appendiceal adenocarcinoma; disease control was achieved in 100% of individuals, with a PFS of 18 months compared to 3 months of disease control on 5-FU based regimens. This is a promising development for those with low-grade, unresectable disease.<sup>92</sup>

Genetic profiles of appendiceal tumors may also influence the effectiveness of cytotoxic regimens. Patients with GNAS-mutation predominant disease are much less likely to have a disease response to chemotherapy, while as many as 50% of patients with RAS-mutation predominant disease may respond.<sup>65</sup> Additionally, some evidence may support the preferential use of irinotecan-containing regimens in RAS-wild type cancers.<sup>64</sup>

**Table 1. Systemic Chemotherapy for Appendiceal Tumors**

Tumor Type and Spread	Stage of therapy	Initial therapy	Subsequent therapy
-----------------------	------------------	-----------------	--------------------

<b>Tumors without peritoneal spread</b>			
Low- or high-grade appendiceal mucinous neoplasm	-	No evidence supports systemic therapy in this population at this time.	
Low-grade/well-differentiated appendiceal adenocarcinoma		No evidence supports systemic therapy in this population at this time.	
Appendiceal adenocarcinoma with nodal involvement or high-risk features (described above)	<i>Neoadjuvant/Conversion</i>	<i>Not recommended</i>	
	<i>Adjuvant (after right hemicolectomy)</i>	Consider: <i>FOLFOX doublet chemotherapy</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy</i>	<i>Regimens as described at left not previously attempted</i>
<b>Tumors with peritoneal spread</b>			
Low-grade appendiceal tumor (low- or high-grade appendiceal mucinous neoplasm, or low-grade/well-differentiated appendiceal adenocarcinoma) with resectable low-grade peritoneal involvement		No evidence supports systemic therapy in this population at this time.	
Low-grade appendiceal tumor (low- or high-grade appendiceal mucinous neoplasm, or low-grade/well-differentiated appendiceal adenocarcinoma) with unresectable peritoneal involvement that is also low-grade		Limited evidence supports a survival benefit for systemic therapy in this population at this time. Use of systemic therapy may be indicated in the setting of a trial such as those described above or certain palliative care pathways. <sup>92</sup>	
Appendiceal adenocarcinoma with resectable low-grade peritoneal involvement, found after definitive resection to have nodal involvement or high-risk features (described above)	<i>Neoadjuvant/Conversion</i>	<i>Not recommended</i>	
	<i>Adjuvant (after complete cytoreduction)</i>	Consider: <i>FOLFOX doublet chemotherapy</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy</i>	<i>Regimens as described at left not previously attempted</i>

Appendiceal adenocarcinoma with unresectable low-grade peritoneal involvement, found to have nodal involvement or high-risk features with or without an attempt at debulking	<i>Perioperative</i>	Consider: <i>FOLFOX or FOLFIRI doublet chemotherapy +/- anti-VEGF</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy +/- anti-VEGF</i>	
	<i>Nonoperative or postoperative (after debulking) for disease control</i>	Consider: <i>FOLFOX doublet chemotherapy</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy</i>  <i>If residual disease after cytoreduction: consider anti-VEGF agents</i>	<i>Regimens as described at left not previously attempted</i>
Any resectable or unresectable appendiceal tumor with any high-grade peritoneal involvement	<i>Neoadjuvant therapy/Conversion (trial of response or empiric regimen)</i>	<i>FOLFOX or FOLFIRI doublet chemotherapy +/- anti-VEGF</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy +/- anti-VEGF</i>	<i>Regimens as described at left not previously attempted</i>
	<i>Perioperative therapy (borderline resectable or cytoreducible lesions)</i>	<i>FOLFOX or FOLFIRI doublet chemotherapy +/- anti-VEGF</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy +/- anti-VEGF</i>	
	<i>Adjuvant/Postoperative (after CRS/HIPEC if residual disease OR incomplete preoperative regimen)</i>	<i>FOLFOX doublet chemotherapy</i>  <i>*FOLFOXIRI or FOLFIRINOX triplet chemotherapy</i>  <i>If residual disease after cytoreduction: consider anti-VEGF agents</i>	<i>Regimens as described at left not previously attempted</i>
<i>*When triplet chemotherapy is considered, it must be with the understanding that adverse events are more common.</i>			

<b>Table 2. Key Question 1: Systemic chemotherapy regimens and timing relative to cytoreduction in peritoneal appendiceal malignancy</b>							
<b>Author and year</b>	<b>Country</b>	<b>Study design</b>	<b>Population</b>	<b>Tumor grade/type</b>	<b>Chemo regimen</b>	<b>Survival/Other outcomes</b>	<b>Adverse events (grade 3/4)</b>
<b>Barrak 2021</b> <sup>31</sup>	US	Retrospective cohort 1994-2020	Patients undergoing CRS +/- IPCT for peritoneal appendiceal disease with mixed neuroendocrine features	6/44 Tang A 25/44 Tang B 13/44 Tang C	NACT: 32/47 No NACT: 12/47	<b>All comers:</b> Median OS 48.5 mo 5-year OS 34.88% 10-year OS 8.72% No overall significant difference/HR for NACT <b>NACT complete responders: 5/32</b> median OS 65 months	NR
<b>Sugarbaker 2021</b> <sup>30</sup>	US	Retrospective cohort 1996-2011	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease including total gastrectomy and temporary high diverting jejunostomy	27/58 DPAM 25/58 PMCA 6/58 PMCA-S	NACT: 10/58 No NACT: 48/58	Median OS 12 years 5-year OS 76% 10-year OS 58% 20-year OS 37%	20/58 (34.5%) grade 3/4; 2/58 (3.4%) post-operative deaths
<b>Sugarbaker 2010</b> <sup>32</sup>	US	Retrospective cohort 01/2005-07/2009	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	34 PMCA 9/34 PMCA-S 7/34 with neuroendocrine component	NACT: 3 mo FOLFOX/XELOX +/- 3 mo additional NACT	Disease stability after NACT: 24/34 clinical 22/34 imaging 17/34 intraop (17 w/progression) Disease response: 7/34 with pathologic partial response 3/24 pathologic complete response	NR
<b>Sugarbaker 2022</b> <sup>33</sup>	US	Retrospective cohort 1989-2020	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	6/39 MACA-intermediate; 6/39 MACA-Grade 1 17/39 MACA-Grade 2 1/39 MACA-Grade 3 (non signet) 9/39 MACA-S	NACT: 25/39	NACT: Median OS 5 years 7/39 patients with major response to NACT  No NACT: Median OS 7.0 years (non-sig difference)  HR for OS of partial/no response/no preop chemo, vs NACT: 4.8	15/39 (38%) had one or more reoperation; 4/39 (11%) had a class 4 adverse event
<b>Bijelic 2012</b> <sup>34</sup>	US	Retrospective cohort	Patients undergoing CRS +/- IPCT for	<b>NACT:</b> 9/34 PMCA-S	NACT: 6 (12/34) or 12 (22/34) cycles of	NACT: Median OS 37.2 mo	NACT: 26/34 grade 3/4

		01/2005-07/2009	peritoneal mucinous appendiceal disease	25/34 PMCA/adenocarcinoid <b>No NACT:</b> 4/24 PMCA-S 20/24 PMCA/adenocarcinoid	FOLFOX (30/34)/XELOX (4/34)	(Median OS 29.5 mo if no histologic response) No NACT: Median OS 50.5 mo (p=0.56)	No NACT: 14/24 grade 3/4 (p=0.16)
<b>Ihemelandu 2016</b> <sup>35</sup>	US	Retrospective cohort 1989-2012	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	<b>NACT:</b> 152/225 PMCA 38/225 PMCA-S 35/225 PMCA-A <b>No NACT:</b> 209/269 PMCA 42/269 PMCA-S 18/269 PMCA-A	NACT: 3-4 cycles FOLFOX/XELOX	Median OS: 45.4 mo for PMCA 18.9 mo for PMCA-S 26.8 mo for PMCA-A (p<0.0001)  HR for OS of no NACT: 0.7 (p=0.171)	NR
<b>Sugarbaker 2023</b> <sup>36</sup>	US	Retrospective cohort 1985-2020	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	37/196 MACA-intermediate 65/196 MACA-1 57/196 MACA-2 6/196 MACA-3 31/196 MACA-S	NACT: 50/196 Response to NACT: 25/196  No NACT: 146/196	NACT: Median OS 6 mo  No NACT: Median OS 14 mo  HR for OS of NACT: 1.6 (p = 0.0268) HR for OS of response to NACT: 1.16 (p = 0.6216)	NR
<b>Mangieri 2022</b> <sup>81</sup>	US	Retrospective cohort	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease discovered to be high-grade on postoperative pathology	<b>NACT:</b> 24/73 signet ring <b>No NACT:</b> 12/53 signet ring	NACT: 73/136 65/73 FOLFOX, 4/73 5-FU + leucovorin, 3/73 Xeloda, 1/73 unknown No NACT: 53/136	NACT: Median OS 2.1 yr  No NACT: Median OS 3.3 yr  OR for 5-year OS of no NACT: 0.164 (p = 0.017) vs NACT OR for 5-year DFS failure of no NACT: 0.263 (p=0.048)	NACT: 13.7% grade III or higher  No NACT: 13.2% (p=0.937)
<b>Votanopoulos 2015</b> <sup>51</sup>	US	Retrospective cohort 1991-2013	Patients undergoing CRS +/- IPCT for peritoneal epithelial appendiceal disease	317/430 low-grade 93/430 high-grade	NACT, ACT, neither, or both (No details or n provided)	High-grade disease: NACT: Median OS 17 mo vs 30 mo for no NACT (p=0.02)  HR of NACT for OS: 2.5 (p=0.006)  ACT:	HR of no NACT for perioperative minor morbidity: 0.52 (0.28-0.94)

						Median OS 32 mo vs 6 mo for no ACT HR of ACT for OS not significant  Low-grade disease: HR of NACT for OS: 2.2 (p=0.04) HR of ACT for OS not significant	Major morbidity: 0.79 (0.41-1.53)
<b>Blackham 2014</b> <sup>52</sup>	US	Retrospective cohort 1997-2011	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	284/393 MCP-L 109/393 MCP-H Of MCP-H: signet ring in 31 w/ SC and 12 w/o SC	<b>NACT:</b> 13/284 MCP-L Median 4.5 mo 37/109 MCP-H Median 4.0 mo  <b>ACT:</b> 9/284 MCP-L Median 4.0 mo 22/109 MCP-H Median 6.0 mo  <b>NACT and ACT:</b> 11/109 MCP-H  Known regimens: 5-FU (MCP-L>MCP-H), FOLFOX, FOLFIRI, +/- anti-EGFR or VEGF	<b>High-grade disease:</b> <b>Any SCT:</b> Median OS 22.1 mo vs 19.6 mo for no SCT (p=0.74)  <b>ACT:</b> Median OS for ACT 36.4 mo vs 16.0 mo for NACT (p=0.07) vs 19.6 mo for no SCT (p = 0.14) Median PFS for ACT 13.6 mo vs 6.8 mo for NACT (p<0.01) vs 7.0 mo for no SCT (p=0.03)  <b>Low-grade disease:</b> <b>Any SCT:</b> Median OS 107 mo vs 72 mo for matched cohort w/no SCT (p=0.46)	NR
<b>Cummins 2016</b> <sup>53</sup>	US	Retrospective cohort 1991-2015	Patients undergoing CRS +/- IPCT for high-grade peritoneal surface malignancy of appendiceal or colonic origin	110/165 high-grade appendiceal 55/165 colonic 54/159 high-grade adenocarcinoma 66/159 adenocarcinoid or goblet cell 39/159 signet ring cells	<b>NACT (within 3 mo of CRS):</b> 55.8%  <b>ACT:</b> 64.7%	<b>NACT:</b> Median OS 14.4 mo vs 20.4 mo for no NACT (p=0.01)  <b>ACT:</b> Median OS 34.8 mo vs 4.8 mo for no ACT (p<0.0001)	NR by chemo group
<b>Munoz-Zuluaga 2019</b> <sup>54</sup>	US	Retrospective cohort 1998-2017	Patients undergoing complete CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	86/151 HGMCP 65/151 HGMCP-S	<b>NACT:</b> 34/86 HGCMP 40/65 HGCMP-S <b>ACT:</b> 34/83 HGCMP 38/61 HGMCP-S	<b>NACT:</b> Adjusted HR for OS vs no NACT: 1.32 (p=0.28)  Adjusted HR for PFS failure vs no NACT: 1.4 (p=0.24)	NR by chemo group

<b>Baron 2023</b> <sup>45</sup>	US	Retrospective cohort 1999-2020	Patients undergoing complete CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal adenocarcinoma	74/180 non-signet/non-goblet 71/180 signet ring cell 35/180 goblet cell	<b>ACT:</b> 27/77 non-signet/goblet 40/77 signet ring cell 10/77 goblet cell <b>No ACT:</b> 47/103 non-signet/goblet 31/103 signet ring cell 25/103 goblet cell	<b>ACT:</b> Median OS 53 mo Median PFS 26 mo  <b>No ACT:</b> Median OS 77 mo (p=0.566) Median PFS 43 mo (p=0.245)  Unadjusted HR for OS vs no ACT: HR = 1.14 (95% CI 0.73-1.78) Unadjusted HR for PFS failure vs no ACT: HR = 1.27 (95% CI 0.85-1.89)	<b>ACT:</b> 10/77 grade III or higher  <b>No ACT:</b> 22/103 grade III or higher
<b>Milovanov 2015</b> <sup>37</sup>	US	Retrospective cohort 1998-2014	Patients undergoing first time CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	<b>Prior SC:</b> 24/30 high grade 18/30 signet ring ACT: 82% (does not divide evenly) <b>No prior SC:</b> 21/42 high grade 10/42 signet ring ACT: 77% (does not divide evenly)	As at left. FOLFOX, FOLFIRI, CAPEOX	1, 2, and 3-year OS Prior SC: 93, 68, and 51% No prior SC: 82, 64, and 60% (p = 0.74)  1, 2, and 3-year PFS Prior SC: 78, 49, and 36% No prior SC: 67, 53, and 53% (p=0.46)	NR by chemo group
<b>Munoz-Zuluaga 2019</b> <sup>46</sup>	US	Retrospective cohort 1998-2017	Patients undergoing first time CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease, excluding prior debulking or >2 lines of systemic therapy	<b>Prior SC (pSC):</b> 36/64 HGMCP-S 49/59 mod-poor diff ACT: 33/59  <b>No prior SC:</b> 25/76 HGMCP-S 36/71 mod-poor diff ACT: 37/75	Median 4 cycles of preoperative FOLFOX, FOLFIRI, 5-FU/folinic acid, +/- anti-VEGF	Median OS 40.3 mo w/pSC vs 86.4 mo without (p=0.006) Median PFS 19 mo w/pSC vs 43 mo without (p=0.007)  <b>HGMCP vs HGMCP-S:</b> No significant differences in relationship between pSC and survival by grade  HR for OS by pSC not significant	Prior SC: 11% grade III or higher  No prior SC: 17% grade III or higher
<b>Morgan 2023</b> <sup>38</sup>	US	Retrospective cohort 2013-2020	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	<b>Doublet:</b> 8/24 mod diff 9/24 poor diff 13/24 signet ring <b>Triplet:</b> 3/18 mod diff	24/42 doublet (FOLFOX, CAPEOX, FOLFIRI); 11/24 +bevacizumab 18/42 triplet	Median doublet OS 32.2 mo vs 23.5 mo for triplet (p = 0.38)  Median doublet RFS 9.3 mo vs 11.2 mo for triplet (p=0.66)	Discontinued for chemotoxicity: 29% (7/24) doublet vs 39% (7/18)

				9/18 poor diff 14/18 signet ring	(FOLFIRINOX, FOLFOXIRI); 12/18 +bevacizumab	<b>Propensity-matched:</b> Median doublet OS 32.3 mo vs 24.6 mo for triplet (p = 0.64)	triplet (p=0.68)
<b>Kolla 2020</b> <sup>47</sup>	US	Retrospective cohort 2006- 2015	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease; chemo only evaluated after complete CRS	(Complete CRS only) 6/68 LAMN 27/68 well-diff MACA 9/68 mod-diff MACA 3/68 poor diff MACA 2/68 unknown MACA 6/68 MACA with signet ring 10/68 signet ring adenocarcinoma 4/68 mod-diff non-MACA 1/68 poor diff non-MACA	26/68 receiving ACT (CAPE, CAPEOX, FOLFOX) 11/33 low- grade/well- differentiated  15/35 non-low- grade/well- differentiated	<b>Non-low-grade:</b> Median OS 9.03 yr for ACT vs 2.88 yr for no ACT (p=0.02)  Median RFS 2.60 yr for ACT vs 1.16 yr for no ACT (p=0.09)  <b>Low-grade:</b> Median OS not different. Median RFS 4.45 yr for ACT vs 2.16 yr for no ACT (p=0.72)	NR
<b>Chen 2020</b> <sup>39</sup>	US	Retrospective cohort 2000- 2017	Patients undergoing CRS +/- IPCT for non- low-grade peritoneal mucinous appendiceal adenocarcinoma	<b>NACT:</b> 49/225 well-diff 38/225 mod-diff 49/225 poorly-diff 44/225 signet ring ACT: 55/225 <b>No NACT:</b> 274/578 well-diff 100/578 mod-diff 65/578 poor diff 69/578 signet ring ACT: 85/578	144/225 FOLFOX 43/225 FOLFIRI 9/225 CAPE 7/225 CAPEOX 7/225 5-FU + leucovorin 18/225 other	Median OS 19 mo for NACT vs 29 mo for no NACT (p<0.001) Adjusted HR of NACT for OS not significant  Median RFS 12 mo for NACT vs 20 mo for no NACT (p<0.001) Adjusted HR of NACT for RFS failure: 2.03 (p=0.001)  <b>Propensity-matched:</b> Median OS not different; adjusted HR of NACT for OS 1.81 (p=0.04) Median RFS 14 mo vs 22 mo for no NACT (p=0.007) Adjusted HR of NACT for RFS failure: 1.93 (p=0.003)	43% grade III or higher in NACT vs 33% without NACT (p<0.001)  No difference in matched analysis
<b>Flood 2023</b> <sup>55</sup>	US	Retrospective cohort 2009- 2020	Patients undergoing CRS +/- IPCT for non- low-grade peritoneal mucinous appendiceal adenocarcinoma	<b>NACT:</b> 5/25 MACA 5/25 intestinal-type adenocarcinoma 15/25 goblet or signet ring cell adenocarcinoma <b>No NACT:</b> 32/61 MACA	<b>NACT:</b> 6-12 cycles of 5-FU plus oxaliplatin and/or irinotecan, with or without bevacizumab or cetuximab 12/25 received ACT, not specified	<b>NACT:</b> 8/25 with some degree of response on imaging 2/25 with complete pathologic response OS at 1, 2, and 3 years: 87.5%, 71%, and 47.3% Univariate HR for OS: 1.49 (p=0.388)	16.3% grade III or higher overall



				5/61 intestinal-type adenocarcinoma 24/61 goblet or signet ring cell adenocarcinoma	<b>No NACT:</b> 24/61 received ACT	Univariate HR for DFS failure: 1.52 (p=0.309)  <b>No NACT:</b> OS at 1, 2, and 3 years: 89.7%, 83.8%, 75.8% <b>ACT:</b> Univariate HR for OS: 1.25 (p=0.665) Univariate HR for DFS failure: 2.29 (p = 0.035)  HR for OS and DFS not significant in multivariable analysis	
<b>Turner 2013</b> <sup>56</sup>	US	Retrospective cohort 2005-2011	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal adenocarcinoma	16/45 signet ring 33/45 mucinous adenocarcinoma 2/45 adenocarcinoid 5/45 well-diff 10/45 mod-diff 16/45 poor-diff	<b>NACT:</b> 26/45 at least 3 months of primarily 5-FU with oxaliplatin or irinotecan, with or without bevacizumab  <b>ACT:</b> 29/45 not otherwise specified	<b>NACT:</b> 15/26 with response 9/26 with stable disease 2/26 with progression Median OS 22 mo  <b>No NACT:</b> Median OS not reached, not statistically different (p-value 0.1191)	<b>NACT:</b> 40% "major"  <b>No NACT:</b> 30% "major"
<b>Hanna 2023</b> <sup>40</sup>	US	Retrospective cohort 2011-2019	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal appendiceal adenocarcinoma	<b>TNT:</b> 12/25 high-grade 13/25 intermediate grade 10/25 signet ring <b>SAND:</b> 4/14 high-grade 10/14 intermediate grade 5/14 signet ring	<b>TNT:</b> 12 cycles preop  <b>SAND:</b> 6 cycles preop, up to 6 cycles postop  5-FU with oxaliplatin or irinotecan, with or without bevacizumab	<b>TNT:</b> Median OS 62.7 mo Median RFS 35.4 mo Recurrence rate 36% Adjusted HR for overall survival: 0.41 (p=0.03) Adjusted HR for RFS: 0.34 (p=0.007)  <b>SAND:</b> 9/14 completed adjuvant regimen Median OS 45.1 mo (p=0.01 vs TNT) Median RFS 12.3 mo (p=0.03 vs TNT) Recurrence rate 71.4% (p=0.03 vs TNT)	Not reported
<b>Spiliotis 2017</b> <sup>60</sup>	Greece	Retrospective cohort 2005-2014	Patients undergoing CRS +/- IPCT for peritoneal mucinous	14/52 DPAM 8/52 PMCA-I 30/52 PMCA	<b>Perioperative SCT:</b> 20/52	<b>Perioperative SCT:</b>	Not reported

			appendiceal neoplasm	25/52 low-grade 27/52 high-grade 21/52 signet ring cell	5-FU or capecitabine with oxaliplatin	Mean OS 24 mo vs 14 mo without (p=0.048); Median DFS 19 mo vs 10 mo without (p = 0.034)  Mixed median and mean values across all histologic subgroups, with benefit displayed in chemotherapy groups	
<b>Benhaim 2019</b> <sup>41</sup>	France	Retrospective cohort 1992-2014	Patients undergoing complete CRS +/- IPCT for peritoneal mucinous appendiceal disease	<b>Non-extensive:</b> 123/184 DPAM 31/184 Hybrid 26/184 PMCA 4/184 unknown 38/184 NACT <b>Extensive PMP:</b> 17/61 DPAM 26/61 Hybrid 16/61 PMCA 2/61 unknown 40/61 NACT	<b>NACT:</b> 38/184 non-extensive 40/61 extensive	<b>NACT:</b> Univariate HR for OS: 2.81 vs no NACT (p=0.00026) Univariate HR for DFS failure: 3.34 vs no NACT (p<0.001)  Neither significant in multivariable analysis	Not reported
<b>Mercier 2019</b> <sup>57</sup>	France	Retrospective cohort 1993-2015	Patients undergoing complete CRS +/- IPCT for peritoneal mucinous appendiceal disease	62/199 WHO low grade 137/199 WHO high grade	<b>NACT</b> 95/257 <b>ACT</b> 36/258	<b>NACT:</b> 6/95 no recurrence 81/95 early recurrence 8/95 late recurrence  <b>No NACT:</b> 27/164 no recurrence 115/164 early recurrence 22/164 late recurrence  Preoperative chemo more common among early recurrence (41.5%) vs late recurrence (28%) (p=0.02)	Not reported
<b>Masckauchan 2019</b> <sup>91</sup>	Canada	Retrospective cohort 2004-2015	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	35/109 DPAM 55/109 PMCA-I 19/109 PMCA	<b>SCT</b> 34/109 in all high-grade and high-tumor load individuals; 3 to 6 mo 5-FU based regimen	<b>SCT</b> Univariate HR for OS: 3.939 (p<0.001) Adjusted HR for OS: 3.507 (p=0.002)	26.1% grade III or higher overall

<b>Acs 2023</b> <sup>42</sup>	Germany	Retrospective cohort 2011-2021	Patients undergoing CRS +/- IPCT for peritoneal appendiceal adenocarcinoma, primary or recurrent	43/84 MACA (17 G1, 19 G2, 7 G3, 4 w/signet ring, 6/84 unknown) 9/84 signet ring cell adenocarcinoma 19/84 intestinal-type adenocarcinoma (2 G1, 10 G2, 7 G3) 8/84 goblet cell 1/84 mixed adenoneurocrine	<b>Prior SCT:</b> 21/55 5-FU with oxaliplatin or irinotecan with or without bevacizumab or cetuximab	<b>Prior SCT:</b> Univariate HR for OS: 1.220 (p=0.571), not significant on multivariable analysis	20.3% grade III or higher overall
<b>Kusamura 2021</b> <sup>43</sup>	Inter-national	Retrospective cohort 1993-2017	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	<b>CRS alone</b> 197/376 low grade 179/376 high grade NACT: 198/376 <b>CRS+HIPEC</b> 1056/1548 low grade 492/1548 high grade NACT: 529/1548	<b>Prior SCT:</b> 198/376 CRS alone 529/1548 CRS-HIPEC	<b>Prior SCT:</b> Multivariable HR for OS: 1.58 (p<0.001)	18.6% grade III or higher overall
<b>Baratti 2008</b> <sup>44</sup>	Italy	Prospective cohort 1996-2007	Patients undergoing CRS +/- IPCT for any mucinous peritoneal disease, excluding age >75, performance status > ECOG2, bowel obstruction, and tumor deposits >0.5cm on surface of small bowel on imaging	99/104 appendiceal Of 41 reviewed: 32/41 LAMN 6/41 MACA 3/41 no tumor 1/104 colon 2/104 ovarian/teratoma 2/104 unknown origin	<b>Prior SCT:</b> 23/95	<b>Prior SCT:</b> Multivariable HR for OS: 2.72 (p=0.0339) Multivariable HR for PFS failure: 2.04 (p=0.0453)	18.7% grade III or higher overall
<b>Schomas 2009</b> <sup>48</sup>	US	Retrospective cohort 1985-2000	Patients undergoing CRS +/- IPCT for peritoneal carcinomatosis of appendiceal origin	82/115 adenocarcinoma 33/115 cystadenocarcinoma 112/115 low-grade 3/115 high-grade	<b>ACT:</b> 22/115 5-FU based regimens	<b>ACT:</b> Overall survival at 5, 10, and 15 years: 48, 14, 14% (p=0.01 vs no ACT) DFS at 5, 10, and 15 years: 16, 11, and 11% (p=0.03 vs no ACT)  <b>No ACT:</b> Overall survival at 5, 10, and 15 years: 72, 47, and 31% DFS at 5, 10, and 15 years: 42, 29, and 22%	Not reported

<b>Arjona-Sanchez 2013</b> <sup>49</sup>	Spain	Retrospective analysis of prospective cohort 1998-2012	Patients undergoing CRS +/- IPCT for non-low-grade peritoneal mucinous appendiceal disease	11/38 PMCA-I NACT: 6 27/38 PMCA NACT: 11 ACT: all	<b>NACT:</b> 17/36 Mean 5 cycles of 5-FU or capecitabine and oxaliplatin, for those with unfavorable histology or high disease burden	<b>NACT:</b> progression on NACT excluded from consideration. Median OS 47 mo Overall survival at 1, 3, and 5 years: 74, 54, and 43% (p=0.068 vs no NACT) DFS at 1 and 3 years for non CC2 patients: 60, 29% (p=0.34 vs no NACT)  <b>No NACT:</b> Median OS 53 mo Overall survival at 1, 3, and 5 years: 100, 100, and 75% DFS at 1 and 3 years for non CC2 patients: 68, 46%	18.4% grade III or higher overall
<b>Ung 2014</b> <sup>58</sup>	Australia	Retrospective cohort 1996-2013	Patients undergoing CRS +/- IPCT for peritoneal mucinous appendiceal disease	<b>146/257 low-grade tumors:</b> 133/146 DPAM 13/146 hybrid tumors NACT: 139/146 ACT: 123/146 <b>111/257 high-grade tumors:</b> 85/111 PMCA 26/111 non-mucinous adenocarcinoma NACT: 67/111 ACT: 28/111	<b>NACT:</b> 205/257 <b>ACT:</b> 98/250	<b>DPAM/hybrid:</b> <b>NACT:</b> Univariate HR for OS: 2.08 (p=0.29)  <b>ACT:</b> Univariate HR for OS: 1.90 (p=0.059)  <b>PMCA:</b> <b>NACT:</b> Univariate HR for OS: no difference  <b>ACT:</b> Univariate HR for overall mortality (i.e. inverse of usual – protective): 2.70 (p=0.001)	46.8% grade III or higher in PMCA  47.3% grade III or higher in DPAM
<b>Baumgartner 2015</b> <sup>72</sup>	US	Retrospective cohort 2007-2013	Patients undergoing CRS +/- IPCT for high-grade peritoneal surface malignancy of appendiceal or colonic origin	9/70 mod-diff 41/70 poorly-diff 20/70 not reported 41/70 mucinous 14/70 signet ring cells	<b>NACT:</b> 59/70, median 12 cycles (0-54) <b>ACT:</b> 34/46 known	No associations between NACT, ACT, and OS or PFS	21/4% grade III or higher overall
<b>Grotz 2017</b> <sup>59</sup>	US	Retrospective analysis of prospective cohort 2004-2014	Patients evaluated for CRS +/- IPCT for non-low-grade peritoneal appendiceal adenocarcinoma	(Cohort undergoing CRS) 78/116 mucinous 38/116 non-mucinous 54/116 mod-diff 62/116 poorly-diff	<b>NACT:</b> 85/116 4-6 cycles FOLFOX with or without bevacizumab	No significant differences in outcomes	18.1% grade III or higher overall at 90 days

				42/116 signet ring cells	<b>ACT:</b> 23/265		
<b>Pallas 2017</b> <sup>50</sup>	Greece	Retrospective cohort 2006-2016	Patients undergoing CRS +/- IPCT for high-grade peritoneal surface malignancy of appendiceal or colonic origin	15/100 appendiceal origin 85/100 colonic origin 58/100 signet ring cells	<b>ACT:</b> 72/100 1 mo after surgery	<b>ACT:</b> Does not reach significance on multivariable analysis for overall survival For RFS failure, HR 9.181 (p=0.002)	26% grade III or higher overall
<p><b>Abbreviations: OM and OS as above; PFS: progression-free survival; RFS: recurrence-/relapse-free survival; DFS: disease-free survival (equivalent to DFS by most metrics); NR: not reported; CRS: cytoreduction; IPCT: intraperitoneal chemotherapy, be that HIPEC, EPIC, or another regimen; SC: systemic chemotherapy, timing otherwise unspecified; pSC: prior SC, otherwise unspecified; NACT: neoadjuvant or preoperative chemotherapy; ACT: adjuvant or postoperative chemotherapy; DPAM: diffuse peritoneal adenomucosis; PMCA: peritoneal mucinous carcinomatosis; MACA: mucinous adenocarcinoma of the appendix; -S: signet ring cell component; PMCA-A: PMCA with adenocarcinoid features (only used where used in the original publication); MCP-L/H: mucinous carcinoma peritonei -low grade and -high grade; HGMCP: high grade mucinous carcinoma peritonei</b></p>							

### Regional chemotherapy regimens

Evidence suggests potential survival benefit from intraperitoneal chemotherapy with optimal cytoreduction for appendiceal neoplasms with peritoneal involvement.<sup>35,42,43,69,86,93–96</sup> In general, the consensus recommendation is to consider intraperitoneal chemotherapy with optimal cytoreduction, but there are still variations in practice.

Mitomycin C (MMC) is the most widely used agent.<sup>35,69,75,93,96–110</sup> Oxaliplatin is also common, given its known activity against gastrointestinal malignancies.<sup>42,94,95,99,111</sup> Oxaliplatin and MMC appear to have similar hematological outcomes, including in a randomized trial; MMC was more commonly associated with leukopenia and oxaliplatin with thrombocytopenia, with no difference in grade 3 and 4 adverse events.<sup>99</sup> A few centers have studied regimens involving of irinotecan, cisplatin, and doxorubicin alone or in addition to MMC or oxaliplatin.<sup>43,75,108,111–116</sup> Data is mixed regarding cisplatin-containing regimens but irinotecan trends toward more inferior outcomes.<sup>42,111</sup>

In studies and centers performing pressurized intraperitoneal aerosol chemotherapy (PIPAC), oxaliplatin is most common, followed by cisplatin and doxorubicin.<sup>117,118</sup> Currently, this consortium recommends PIPAC only in the setting of a clinical trial as early phase trials are still in progress. A small number of centers offer early postoperative intraperitoneal chemotherapy (EPIC); when implemented, 5-FU is typically used, with some initially promising data.<sup>42,119,120</sup> The ICARUS and other trials are ongoing to further assess the role for EPIC in appendiceal cancer.<sup>121</sup>

**Table 3. Regional Chemotherapy for Appendiceal Neoplasms**

Regional Regimens	Currently in use
<b>HIPEC</b>	Mitomycin C Oxaliplatin Not recommended at this time: combinations based on irinotecan, cisplatin, doxorubicin
<b>PIPAC</b>	Oxaliplatin Cisplatin/doxorubicin
<b>IP/EPIC</b>	5-fluorouracil (FUDR) used in some centers

‡ Use of regional perfusion chemotherapy is extremely institution- and setting-specific, and there is neither adequate literature nor strong consensus as to the most effective regimen or mode of administration. This table is included for reference into current practices at time of writing.

### BASIC PRINCIPLES OF PATHOLOGY OF APPENDICEAL TUMORS

An overview of challenging issues in appendix tumor pathology will be described in the second part of these guidelines alongside the guideline for peritoneal disease. Key points are summarized here.

Critical points of differentiation that apply generally to pathologic evaluation of appendiceal tumors are those that are most likely to be misclassified, and those that lead to clinically relevant management differences. Expert pathology review should generally be pursued any time patients are referred from other systems to referral centers, when there is significant discordance between primary and peritoneal findings, and when signet ring cells are identified. Clinically relevant distinctions that should be closely assessed include the presence of an invasive component, which differentiates between LAMN and well-differentiated adenocarcinoma in lower grade lesions, and HAMN and adenocarcinoma in

higher grade lesions. The latter should be particularly closely examined because it is common for an invasive component of HAMN to be missed.<sup>122–124</sup> Well-differentiated mucinous adenocarcinoma must also be cautiously designated, as it affects the recommended extent of surgical resection.

While localized disease, by definition, should not include significant gross peritoneal disease, there may be surface mucin or perforation in specimens from disease presentations initially evaluated by surgeons as localized. Correct identification of the cellularity of extra-appendiceal mucin is critical to determine whether disease should be treated according to the peritoneal management pathway.

## APPENDICEAL MUCINOUS NEOPLASMS

### Consensus Updates

One major change from the 2018 guideline (Figure 2) is more definitive recommendations for surveillance vs cytoreduction with or without IPCT in disease that is otherwise localized but with limited regional spread. More specific recommendations address positive margins and perforation, with an emphasis on the most minimally invasive treatment possible to achieve negative margins.

**Table 4. Delphi 1 agreement tables (% agreement includes agree and strongly agree)**

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agree
<b>Block 1</b>	91	38	5	4	0	138	93%
<b>Block 2</b>	104	30	4	0	0	138	97%
<b>Block 3</b>	92	37	7	2	0	138	93%
<b>Block 4</b>	93	37	7	1	0	138	94%
<b>Block 5</b>	90	37	4	7	0	138	92%
<b>Block 6</b>	94	40	4	0	0	138	97%
<b>Block 7</b>	93	39	4	2	0	138	96%
<b>Block 8</b>	93	38	5	2	0	138	95%
<b>Block 9</b>	94	38	4	1	1	138	96%
<b>Block 10</b>	99	33	5	0	1	138	96%
<b>Block 11</b>	83	42	9	4	0	138	91%


**Table 5. Delphi 2 agreement tables (% agreement includes agree and strongly agree)**

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agree
<b>Block 1</b>	124	8	1	0	0	133	99%
<b>Block 2</b>	123	8	1	1	0	133	98%
<b>Block 3</b>	120	8	1	4	0	133	96%
<b>Block 4</b>	125	6	2	0	0	133	98%

<b>Block 5</b>	122	8	1	2	0	133	98%
<b>Block 6</b>	123	9	1	0	0	133	99%
<b>Block 7</b>	122	8	1	2	0	133	98%
<b>Block 8</b>	124	7	1	1	0	133	98%
<b>Block 9</b>	120	8	1	4	0	133	96%
<b>Block 10</b>	123	9	1	0	0	133	99%
<b>Block 11</b>	116	11	2	3	1	133	95%



Figure 2. Epithelial Appendiceal Mucinous Neoplasm Pathway



### *Block 1*

When first detected on imaging, or as a pathological finding during or after appendectomy, initial workup of a suspected of AMN should include a detailed history and physical, tumor markers including CEA, CA125, CA19-9, and CRP, and abdominopelvic cross-sectional imaging if not already performed. Serum markers are useful for prognostication, monitoring treatment response, and identifying recurrence. Imaging is additionally useful for evaluating peritoneal and other distant disease sites and surgical planning.<sup>125–128</sup> Imaging findings that may be seen in appendiceal neoplasms include focal distal appendiceal dilatation, size over 2 cm, curvilinear calcifications, wall irregularity, and absence of periappendiceal fat stranding; calcifications are specific but not sensitive.<sup>129,130</sup>

Colonoscopy should be performed to rule out synchronous lesions that might affect surgical planning, which occur in 14-42% of this population.<sup>131,132</sup> Somatic and tumor genetic profiling may be considered but minimal evidence exists for AMN.

Patients with AMNs should be discussed at multidisciplinary tumor board; while many AMNs can be treated with resection alone, imaging and treatment plan review can help prepare the care team for unexpected contingencies. Tissue samples should be reviewed by an expert pathologist. Patients should also be evaluated for additional support needs, which may include referral to patient support groups, social work consultation, financial support resources, psychosocial support resources, and fertility counseling.

Where AMNs are diagnosed by any non-surgical means (typically imaging), the next step should be surgical exploration by least invasive safe approach. In most cases this will be diagnostic laparoscopy, but the surgeon's best judgement must be employed. If lesions suspicious for peritoneal disease are identified, biopsies should be taken.

**% Agreement:** First round 93%, second round 99%

### *Block 2*

If no gross peritoneal spread of disease or macroscopic extra-appendiceal mucin is noted on surgical exploration, appendectomy alone should be performed to a negative margin.<sup>133–135</sup>

**% Agreement:** First round 97%, second round 98%

### *Block 3*

If final surgical margins are negative, attention must be turned to the presence or absence of perforation and extra-appendiceal mucin or neoplastic cells. If all of the above are absent, surveillance can be employed selectively. In many cases surveillance will not be necessary; however, the risk of recurrence is never zero, as it is possible for an AMN to perforate and then re-seal, leading to a theoretical increased risk of peritoneal progression or recurrence.<sup>134–136</sup>

**% Agreement:** First round 93%, second round 96%

### *Block 4*

If final surgical margins are negative but microscopic perforation is noted, or there is microscopic extra-appendiceal mucin or neoplastic cells confined to the surface of the appendix, surveillance is indicated as described in block 11.<sup>134–136</sup> Microscopic extra-

appendiceal mucin and neoplastic cells confined to the surface of the appendiceal specimen alone still constitute a negative margin.

**% Agreement:** First round 94%, second round 98%

#### *Block 5*

If final surgical margins are positive, with viable neoplastic epithelial cells at the margin (not acellular mucin alone) or there is concern for the same, repeat resection should be performed to a negative margin, although data suggests in some series that even gross resection may be adequate.<sup>134–136</sup> Historically, ileocectomy or cecectomy have been performed, but the consensus recommendation is to perform the most conservative resection possible, such as cuff resection. Anastomosis should be avoided if possible. Then surveillance must be performed regularly. Observation may be considered for those patients at high risk for surgical morbidity, in whom there may be less benefit from oncologic resection.

**% Agreement:** First round 92%, second round 98%

#### *Block 6*

If, on index surgical exploration, gross peritoneal spread or extra-appendiceal mucin is noted, a definitive diagnosis must be confirmed. Biopsy of the sites of peritoneal spread and appendectomy should be performed if technically feasible, such that pathologic review can clearly confirm diagnosis and disease grade to guide therapy.

**% Agreement:** First round 97%, second round 99%

#### *Block 7*

If extra-appendiceal disease is limited to localized acellular mucin only by direct visualization, and all disease is completely resected (the equivalent of a complete/adequate cytoreduction), no further surgical management is indicated. Rate of recurrence is as low as 4%.<sup>137</sup> The definition of localized acellular mucin is ultimately dependent upon intraoperative surgeon judgement, but expert consensus recommends defining this as disease limited to the meso-appendiceal fold and peri-appendiceal recesses. Regular surveillance is indicated and should follow the recommendations in block 11.<sup>138</sup>

**% Agreement:** First round 96%, second round 98%

#### *Block 8*

If extra-appendiceal disease is limited to acellular mucin in the right lower quadrant, but residual disease is left at the time of initial exploration with or without an attempt at resection (such as in those patients referred from outside institutions or with otherwise previous incomplete cytoreduction), evaluation should be initiated for cytoreduction with or without intraperitoneal chemotherapy; given the limited data on recurrence in this subpopulation, this is primarily an expert consensus-based recommendation.

**% Agreement:** First round 95%, second round 98%

### *Block 9*

If surgical exploration reveals extra-appendiceal acellular mucin that is more widely disseminated than the peri-appendiceal region, or cellular mucin, refer to the peritoneal disease pathway, as a more comprehensive approach focused on regionally advanced disease must be pursued. Recurrence estimates for localized cellular mucin (any grade) range widely from 33-75%, comparable to disseminated disease, justifying a more aggressive approach.<sup>137,139</sup>

**% Agreement:** First round 96%, second round 96%

### *Block 10*

If there is evidence of recurrent or progressive disease during surveillance, this would be, by definition, peritoneal disease, and care should progress to the peritoneal pathway.

**% Agreement:** First round 96%, second round 99%

### *Block 11*

When indicated, surveillance should include regular interval history and physical as well as imaging and tumor markers. Either CT or MRI are acceptable; modality should be chosen for consistency and expertise in institutional practice as no clear evidence identifies a the superior exam. Tumor markers should include CEA and any other markers that are noted to be elevated at initial evaluation, or at any point in treatment. No studies provide strong evidence for duration and frequency, but a single retrospective study from the US HIPEC collaborative demonstrated imaging surveillance every 6 to 12 months to be non-inferior to more frequent schedules.<sup>140</sup> Recurrence is most common within approximately the first three years postoperatively, and plateaus at approximately six years.<sup>141,142</sup> Consensus therefore recommends surveillance every 6 to 12 months for 5 to 10 years; higher-grade lesions and any degree of peritoneal involvement are indications for more intense surveillance.

As cross-sectional imaging is not sensitive for early peritoneal disease, high-risk pathologic features may merit second-look laparoscopy in select cases, but this should not be pursued for the majority of patients with AMNs.<sup>140</sup> There is no definitive indication for ctDNA surveillance in AMNs.

**% Agreement:** First round 91%, second round 95%

## **APPENDICEAL ADENOCARCINOMA**

### **Consensus Results and Updates**

This pathway (Figure 3) summarizes recommendations for both mucinous and non-mucinous tumors, inclusive of goblet cell but exclusive of neuroendocrine tumors. In addition to reorganization of peritoneal disease, other changes include updated criteria for systemic chemotherapy, a more comprehensive initial workup, and cohesive surveillance recommendations.

**Table 6. Delphi 1 agreement tables (% agreement includes agree and strongly agree)**


	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agree
<b>Block 1</b>	98	34	2	3	1	138	96%
<b>Block 2</b>	102	28	5	2	1	138	94%
<b>Block 3</b>	98	28	6	6	0	138	91%
<b>Block 4</b>	102	31	5	0	0	138	96%
<b>Block 5</b>	100	34	4	0	0	138	97%
<b>Block 6</b>	99	33	5	1	0	138	96%
<b>Block 7</b>	89	35	7	7	0	138	90%

**Table 7. Delphi 2 agreement tables (% agreement includes agree and strongly agree)**

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Total	% Agree
<b>Block 1</b>	124	8	0	1	0	133	99%
<b>Block 2</b>	124	5	1	3	0	133	97%
<b>Block 3</b>	123	8	2	0	0	133	98%
<b>Block 4</b>	123	8	1	1	0	133	98%
<b>Block 5</b>	127	5	1	0	0	133	99%
<b>Block 6</b>	122	10	1	0	0	133	99%
<b>Block 7</b>	116	11	3	2	1	133	95%

**Figure 3. Appendiceal Adenocarcinoma Pathway**

**Appendiceal Adenocarcinoma**



### *Block 1*

As with AMN, appendiceal adenocarcinoma may be detected on diagnostic imaging or incidentally following appendectomy. Initial evaluation and management should mirror that of the AMN pathway.<sup>131,132</sup> As discussed above, germline testing may be considered in conjunction with family cancer history for research purposes and assessment of hereditary cancer risk.<sup>89,143–145</sup> Comprehensive tumor profiling should be considered to identify potential molecular targets.<sup>125–128,143,144</sup> Of note, ctDNA testing may be considered particularly for patients with high-grade or signet ring cell pathology as it is useful for prognostication, although evidence is limited in appendix cancer compared to metastatic colorectal cancer.<sup>146</sup>

**% Agreement:** First round 96%, second round 99%

### *Block 2*

Right hemicolectomy (RHC) with oncologic lymphadenectomy should be pursued for most cases of appendiceal adenocarcinoma in suitable surgical candidates. Currently this is interpreted as the 12-node yield required in colon cancers. Observational data shows survival benefit with at least 10 nodes.<sup>147</sup> Although stage migration and limitations of current research may contribute to the observed benefit of RHC, it has been associated with survival benefit in most mucinous adenocarcinomas with a stage greater than 1, and any non-mucinous adenocarcinoma.<sup>148,149</sup>

The exception to this is well-differentiated mucinous adenocarcinoma that is completely confined to the appendix with negative margins and no concern for more distant disease. The rate of lymph node positivity has been shown to be low in well- and some moderately-differentiated mucinous lesions, decreasing the survival benefit of RHC.<sup>72,133,150</sup>

**% Agreement:** First round 94%, second round 97%

### *Block 3*

Patients with stage III appendiceal adenocarcinoma (spread to at least one regional lymph node) or stage II appendiceal adenocarcinoma with any high-risk features should be considered for adjuvant systemic chemotherapy following surgical resection.<sup>52,54,60,72,73,73–78</sup> High-risk features are summarized in the systemic chemotherapy section above.<sup>52,54,71–77,147</sup> Adjuvant chemotherapy regimens, described under the systemic chemotherapy section, typically last 3-6 months, depending on patient toleration, with a goal of 6 months of therapy.<sup>26,32,57</sup> Patients should be subsequently surveilled, as described in Block 7.

**% Agreement:** First round 91%, second round 98%

### *Block 4*

Patients with stage I and II appendiceal adenocarcinoma without high-risk features as defined above, should be surveilled following surgical resection, as described in block 7, as there is insufficient evidence to suggest that systemic chemotherapy is beneficial in low risk lesions after complete resection.<sup>71</sup>

**% Agreement:** First round 96%, second round 98%

### *Block 5*

If recurrent disease is detected on initial diagnostic workup or during surgical resection, management should follow the pathway described for appendiceal tumors with peritoneal disease, which will be presented separately and will address both peritoneal and extra-peritoneal disease.

**% Agreement:** First round 97%, second round 99%

### *Block 6*

Although not an absolute contraindication to resection in oligometastatic disease, appendiceal adenocarcinoma with extraperitoneal spread at diagnosis is a poor prognostic indicator, and patients presenting in this setting are unlikely to be candidates for definitive surgical resection.<sup>151</sup> Through joint decision-making, clinicians and patients may consider systemic chemotherapy, clinical trials, or best supportive care alone. Multidisciplinary oncologic care including considering palliative consultation is recommended. Surgical intervention may be appropriate for symptom control. Depending on response to intervention, patients may be re-evaluated for debulking or more definitive cytoreductive surgery.

**% Agreement:** First round 96%, second round 99%

### *Block 7*

Imaging and clinical surveillance with the same elements as for AMN is recommended at a frequency of every 3-6 months for 2-4 years, followed by annually for 5 to 10 years. This is more frequent than recommended for AMNs, given the higher recurrence rates in this population in the first year after resection, but is similar to surveillance for higher grade colorectal disease.<sup>140-142</sup> As with AMN, cross-sectional imaging is not sensitive for early peritoneal disease, thus second-look laparoscopy may be considered where there is concern for peritoneal recurrence.<sup>140</sup> Again, interval testing for circulating tumor DNA levels should also be considered, particularly for patients with high-grade or signet-ring positive pathology.<sup>146</sup>

**% Agreement:** First round 90%, second round 95%

## **DISCUSSION**

This text summarizes two of three consensus guideline pathways regarding the management of appendiceal tumors without peritoneal involvement. Consensus was achieved after two rounds of review by a multidisciplinary group across all pathway blocks.

Most evidence regarding the treatment of appendiceal malignancy remains observational at best; however, the volume of data has increased, and there is incrementally improving understanding of the role of systemic chemotherapy. One of the chief benefits of this update is unification of recommendations both across consensus group members with multiple different roles in the comprehensive cancer care field, and across a single unified pathologic grading system. Major changes to emphasize in localized disease recommendations are the new preferential recommendations for margin resection only for LAMN (avoiding segmental resections and anastomoses where possible) and clarified recommendations regarding chemotherapy.



Limitations of the consensus include the retrospective and observational nature of almost all relevant literature in appendiceal neoplasm management. The role of intraperitoneal chemotherapy remains highly controversial among consensus members, and thus no explicit recommendation is presented here. The increased diversity in expertise represented in this consensus group is a major strength.

### **Comparison to other international guidelines**

Both the American Society of Colorectal Surgeons (2019) and the Peritoneal Surface Oncology Group International (2021) have published their own consensus guidelines since the development of the Chicago Consensus, but both have limitations.<sup>152,153</sup> The ASCRS guidelines are surgeon-focused, while PSOGI guidelines are more relevant to the European practice environment and do not expand upon certain grade-by-grade distinctions in management which have been demonstrated to be clinically relevant. The PSOGI guidelines focus on peritoneal disease but also include some guidelines relevant to localized disease as here. First and foremost, they sit within the larger ecosystem of common PSOGI terminology and rely on the PSOGI pathologic classification system.<sup>152</sup> Initial evaluation guidelines are similar to this consensus, except of CRP or any genetic workup is not recommended. Surgical recommendations, including trocar placement (midline to allow for port excision), are more specific, although diagnostic laparoscopy is not as strongly recommended prior to resection; our consortium guidelines essentially require tissue diagnosis.

PSOGI presents recommendations separately for goblet-cell adenocarcinoma (GCA), instead of their inclusion in this consensus along with other non-mucinous adenocarcinoma. PSOGI suggests hemicolectomy may not be necessary in the lowest grade tumors (WHO grade 1 GCA or Tang A) confined to the appendix without high-risk features, while our group at this time recommends right hemicolectomy without exception. Conversely, PSOGI supports consideration of right hemicolectomy for HAMN even without peritoneal disease, while the PSM consortium favors resection to negative margins only. The PSOGI consensus also suggests perforation may be an indication to consider cytoreduction, but our group recommends cytoreduction only if there is demonstrable peritoneal disease of either cellular character or outside the immediate peri-appendiceal region. In terms of systemic chemotherapy, PSOGI specifically recommends a 5-FU backbone and an alkylating agent, as well as neo-angiogenesis inhibitors where resection is incomplete or not performed; indications are generally similar although no preference is given for preoperative vs postoperative timing.<sup>152</sup>

The ASCRS guidelines are from a focused surgical perspective with some salient differences, including that no exception to hemicolectomy is made for well-differentiated and otherwise localized adenocarcinoma. Recommendations regarding systemic chemotherapy are very limited and only extend to unlikely benefit in low-grade lesions and possible benefit in HAMN.<sup>153</sup>

The Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology recently published recommendations as well. Recommendations overlap in most areas with PSOGI, including using PSOGI terminology, considering hemicolectomy for HAMN, and pursuing cecectomy or ileocectomy for margin involvement in LAMN instead of conservative margin resection alone. Similarly, where cellularity or dissemination of peritoneal mucin is required to consider cytoreduction in the PSM consortium guidelines, perforation alone is grounds for considering CRS/HIPEC in the SICO consensus.<sup>154</sup>

## **Patient perspective**

Advocacy groups such as PMP Pals and Appendix Cancer Pseudomyxoma Peritonei Research Foundation (ACPMP) are key resources both directly to patients and families, and indirectly by engaging with research initiatives and guiding clinical practice. Diagnosis with rare malignancies such as appendix tumors often leaves patients and their caregivers feeling abandoned and without options. Moreover, the process of treating appendiceal cancer is far from benign, with long-lasting effects on physical, sexual, and mental health for which patients and families are often not adequately prepared. Respondents identified strong community as crucial to alleviating those feelings, including close relationships with a network of oncologists, surgeons, advocacy groups, and family, and for some, integration of alternative, holistic, and palliative practitioners into routine care. The multidisciplinary nature of this consensus seeks to produce a cohesive approach that facilitates an integrated support network.

Responses from advocacy groups emphasize that quality of life and survival are paramount in deciding on treatment modalities, but that those decisions are not always obvious, especially during surveillance following surgery. One respondent described the experience as a “vast wasteland,” with patients “left to wander a five-year journey with little on the horizon.” Well-designed, accessible online resources are key roadmaps for many, while it is access to clinical trials that often provides direction to that journey by offering hope and a sense of autonomy. However, some patient and caregiver advocates report struggling to navigate this process due to constraints of geography and medical insurance. While this guideline emphasizes referral to clinical trials, equitable access to trials for all has not been achieved. Patient advocates emphasize that current research and scholarship involving appendiceal malignancies would benefit from a louder patient voice, whether it be in choice of study design, deciding on outcomes of interest, or educational initiatives and communication.

Ultimately, improving patients’ experience hinges on clarifying the treatment journey, limiting isolation, and fostering hope where possible.

## **Future scope**

Recommendations related to systemic chemotherapy are in need of ongoing study as outcomes remain poor, particularly in patients with high grade disease. A clear need remains for judiciously designed prospective trials to identify the optimal sequence and delivery of treatment modalities for patients with appendiceal tumors; some are in current development, particularly to investigate the neoadjuvant setting. Most randomized trial schemata are difficult to employ in this patient population, but recent work using crossover designs has shown promise.<sup>68</sup>

Further work is needed to explore quality of life outcomes for patients with appendix tumors, as the relative rarity of their disease leaves them with less support than individuals facing more common cancers.

## **CONCLUSIONS**

In conclusion, herein is reported an updated Delphi consensus of management guidelines concerning appendiceal tumors without peritoneal involvement. Importantly, this consensus group contained experts across multiple disciplines relevant to cancer care, including medical oncologists, surgical oncologists, pathologists, radiologists, palliative care specialists, and patient advocates. Surgical resection remains the primary modality of up-

front definitive treatment in presentations without peritoneal involvement. Systemic chemotherapy should be considered for high-risk pathologies. Regular surveillance should be performed for all patients with appendiceal tumors, save the lowest-grade, lowest risk LAMNs after complete resection with no additional risk factors.

## References

1. McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix. *Cancer*. 2002;94(12):3307-3312. doi:10.1002/cncr.10589
2. Salazar MC, Canavan ME, Chilakamarry S, Boffa DJ, Schuster KM. Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. In: *Journal of the American College of Surgeons*. Vol 234. Lippincott Williams and Wilkins; 2022:1082-1089. doi:10.1097/XCS.000000000000172
3. Marmor S, Portschy PR, Tuttle TM, Virnig BA. The Rise in Appendiceal Cancer Incidence: 2000–2009. *Journal of Gastrointestinal Surgery*. 2015;19(4):743-750. doi:10.1007/s11605-014-2726-7
4. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors. *Dis Colon Rectum*. 1998;41(1):75-80. doi:10.1007/BF02236899
5. Schwartz JA, Forleiter C, Lee D, Kim GJ. Occult Appendiceal Neoplasms in Acute and Chronic Appendicitis: A Single-Institution Experience of 1793 Appendectomies. *Am Surg*. 2017;83(12):1381-1385.
6. Lu P, McCarty JC, Fields AC, et al. Risk of appendiceal cancer in patients undergoing appendectomy for appendicitis in the era of increasing nonoperative management. *J Surg Oncol*. 2019;120(3):452-459. doi:10.1002/jso.25608
7. Teixeira FJR, Couto Netto SD do, Akaishi EH, Utiyama EM, Menegozzo CAM, Rocha MC. Acute appendicitis, inflammatory appendiceal mass and the risk of a hidden malignant tumor: a systematic review of the literature. *World Journal of Emergency Surgery*. 2017;12(1):12. doi:10.1186/s13017-017-0122-9
8. Alajääski J, Lietzén E, Grönroos JM, et al. The association between appendicitis severity and patient age with appendiceal neoplasm histology—a population-based study. *Int J Colorectal Dis*. 2022;37(5):1173-1180. doi:10.1007/s00384-022-04132-8
9. Loftus TJ, Raymond SL, Sarosi GA, et al. Predicting appendiceal tumors among patients with appendicitis. *Journal of Trauma and Acute Care Surgery*. 2017;82(4):771-775. doi:10.1097/TA.0000000000001378
10. Carpenter SG, Chapital AB, Merritt M V, Johnson DJ. Increased risk of neoplasm in appendicitis treated with interval appendectomy: single-institution experience and literature review. *Am Surg*. 2012;78(3):339-343.
11. Furman MJ, Cahan M, Cohen P, Lambert LA. Increased Risk of Mucinous Neoplasm of the Appendix in Adults Undergoing Interval Appendectomy. *JAMA Surg*. 2013;148(8):703. doi:10.1001/jamasurg.2013.1212
12. Mällinen J, Rautio T, Grönroos J, et al. Risk of Appendiceal Neoplasm in Periappendicular Abscess in Patients Treated With Interval Appendectomy vs Follow-up With Magnetic Resonance Imaging. *JAMA Surg*. 2019;154(3):200. doi:10.1001/jamasurg.2018.4373
13. Valasek MA, Thung I, Gollapalle E, et al. Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. *PLoS One*. 2017;12(6):e0179216. doi:10.1371/journal.pone.0179216
14. Turaga KK, Pappas SG, Gamblin TC. Importance of Histologic Subtype in the Staging of Appendiceal Tumors. *Ann Surg Oncol*. 2012;19(5):1379-1385. doi:10.1245/s10434-012-2238-1

15. Gibbs T, Washington MK, Eng C, Idrees K, Davis J, Holowatyj AN. Histologic and racial/ethnic patterns of appendiceal cancer among young patients. *Cancer Epidemiology Biomarkers and Prevention*. 2021;30(6):1149-1155. doi:10.1158/1055-9965.EPI-20-1505
16. Shaib WL, Goodman M, Chen Z, et al. Incidence and Survival of Appendiceal Mucinous Neoplasms. *American Journal of Clinical Oncology: Cancer Clinical Trials*. 2017;40(6):569-573. doi:10.1097/COC.0000000000000210
17. Xu W, Jia S, Zhang Y, et al. Prognostic nomograms for patients undergoing radical operation for stage I-III appendiceal adenocarcinoma: A surveillance, epidemiology, and end results database analysis. *J Cancer Res Ther*. 2021;17(7):1656-1664. doi:10.4103/jcrt.jcrt\_1283\_21
18. Elias H, Galata C, Warschkow R, et al. Survival after resection of appendiceal carcinoma by hemicolectomy and less radical than hemicolectomy: a population-based propensity score matched analysis. *Colorectal Disease*. 2017;19(10):895-906. doi:10.1111/codi.13746
19. Shannon AB, Song Y, Roses RE, Fraker DL, Miura JT, Karakousis GC. National trends in the presentation of surgically resected appendiceal adenocarcinoma over a decade. *J Surg Oncol*. 2021;123(2):606-613. doi:10.1002/jso.26295
20. Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. *Dis Colon Rectum*. 1995;38(8):848-852. doi:10.1007/BF02049842
21. Nitecki SS, Wolff BG, Schlinkert R, Sarr MG. The Natural History of Surgically Treated Primary Adenocarcinoma of the Appendix. *Ann Surg*. 1994;219(1):51-57. doi:10.1097/0000658-199401000-00009
22. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. *Cancer*. 1995;75(3):757-768. doi:10.1002/1097-0142(19950201)75:3<757::AID-CNCR2820750303>3.0.CO;2-F
23. Winicki NM, Radomski SN, Ciftci Y, Sabit AH, Johnston FM, Greer JB. Mortality risk prediction for primary appendiceal cancer. *Surgery*. Published online March 2024. doi:10.1016/j.surg.2024.02.014
24. Shen JP, Yousef AM, Zeineddine FA, et al. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. In: *JAMA Network Open*. Vol 6. American Medical Association; 2023. doi:10.1001/jamanetworkopen.2023.16161
25. Hoehn RS, Rieser CJ, Choudry MH, Melnitchouk N, Hechtman J, Bahary N. Current Management of Appendiceal Neoplasms. *American Society of Clinical Oncology Educational Book*. 2021;(41):118-132. doi:10.1200/EDBK\_321009
26. Schuitevoerder D, Plana A, Izquierdo FJ, et al. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. *Ann Surg Oncol*. 2020;27(6):1753-1760. doi:10.1245/s10434-020-08316-w
27. PSM Methods Writing Group. Consensus Guidelines for the Management of Peritoneal Surface Malignancies: Introduction and Methodology. *Submitted*. Published online 2024.
28. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Published online 2000.

29. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z
30. Sugarbaker PH, Chang D. Treatment of advanced pseudomyxoma peritonei using cytoreductive surgery including total gastrectomy and perioperative chemotherapy. *J Surg Oncol.* 2021;124(3):378-389. doi:10.1002/jso.26506
31. Barrak D, Desale S, Yoon JJ, et al. Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy. *Eur J Surg Oncol.* 2021;47(6):1278-1285. doi:10.1016/j.ejso.2021.01.010
32. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. *J Surg Oncol.* 2010;102(6):576-581. doi:10.1002/jso.21679
33. Sugarbaker PH, Chang D. Lymph node positive pseudomyxoma peritonei. *Eur J Surg Oncol.* 2022;48(12):2369-2377. doi:10.1016/j.ejso.2022.07.018
34. Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH. Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival. *Gastroenterol Res Pract.* 2012;2012:163284. doi:10.1155/2012/163284
35. Ihemelandu C, Sugarbaker PH. Clinicopathologic and Prognostic Features in Patients with Peritoneal Metastasis from Mucinous Adenocarcinoma, Adenocarcinoma with Signet Ring Cells, and Adenocarcinoid of the Appendix Treated with Cytoreductive Surgery and Perioperative Intraperitoneal C. *Ann Surg Oncol.* 2016;23(5):1474-1480. doi:10.1245/s10434-015-4995-0
36. Sugarbaker PH, Chang D, Liang JJ. Similar Survival Among All Subtypes of Mucinous Appendiceal Adenocarcinoma Except the Intermediate Subtype, Which Shows an Improved Survival. *Ann Surg Oncol.* 2023;30(3):1874-1885. doi:10.1245/s10434-022-12864-8
37. Milovanov V, Sardi A, Ledakis P, et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). *European Journal of Surgical Oncology (EJSO).* 2015;41(5):707-712. doi:https://doi.org/10.1016/j.ejso.2015.01.005
38. Morgan RB, Dhiman A, Kim AC, et al. Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. *Journal of Gastrointestinal Surgery.* 2023;27(11):2560-2562. doi:10.1007/s11605-023-05747-0
39. Chen JC, Beal EW, Hays J, Pawlik TM, Abdel-Misih S, Cloyd JM. Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer. *J Surg Oncol.* 2020;122(3):388-398. doi:10.1002/jso.25967
40. Benhaim L, Faron M, Gelli M, et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. *Surg Oncol.* 2019;29:78-83. doi:10.1016/j.suronc.2019.03.004
41. Acs M, Gerken M, Zustin J, Blaj S, Isgandarova S, Piso P. Prolonged Survival in Peritoneal Metastatic Appendiceal Carcinoma Patients Treated With Combined Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *J Surg Res.* 2023;283:839-852. doi:10.1016/j.jss.2022.10.083

42. Kusamura S, Barretta F, Yonemura Y, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. *JAMA Surg.* 2021;156(3):e206363-e206363. doi:10.1001/jamasurg.2020.6363
43. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). *Ann Surg Oncol.* 2008;15(2):526-534. doi:10.1245/s10434-007-9691-2
44. Mangieri CW, Moaven O, Valenzuela CD, et al. Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol.* 2022;29(4):2641-2648. doi:10.1245/s10434-021-11153-0
45. Masckauchan D, Trabuasi N, Dubé P, et al. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis. *Surg Oncol.* 2019;28:69-75. doi:10.1016/j.suronc.2018.11.006
46. Munoz-Zuluaga CA, King MC, Ledakis P, et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. *Eur J Surg Oncol.* 2019;45(9):1598-1606. doi:10.1016/j.ejso.2019.05.008
47. Baron E, Sardi A, King MC, et al. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. *Eur J Surg Oncol.* 2023;49(1):179-187. doi:10.1016/j.ejso.2022.08.022
48. Kolla BC, Petersen A, Chengappa M, et al. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. *Cancer Med.* 2020;9(10):3400-3406. doi:10.1002/cam4.3009
49. Schomas DA, Miller RC, Donohue JH, et al. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience. *Ann Surg.* 2009;249(4):588-595. doi:10.1097/SLA.0b013e31819ec7e3
50. Arjona-Sanchez A, Muñoz-Casares FC, Casado-Adam A, et al. Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy. *World J Surg.* 2013;37(6):1263-1270. doi:10.1007/s00268-013-2000-2
51. Pallas N, Karamveri C, Kyziridis D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis. *J BUON.* 2017;22(6):1547-1553.
52. Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal Surface Disease (PSD) from Appendiceal Cancer Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Overview of 481 Cases. *Ann Surg Oncol.* 2015;22(4):1274-1279. doi:10.1245/s10434-014-4147-y
53. Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and

- hyperthermic intraperitoneal chemotherapy. *J Surg Oncol*. 2014;109(7):740-745. doi:10.1002/jso.23547
54. Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *J Gastrointest Oncol*. 2016;7(1):3-9. doi:10.3978/j.issn.2078-6891.2015.101
  55. Munoz-Zuluaga C, Sardi A, King MC, et al. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2019;26(2):473-481. doi:10.1245/s10434-018-7007-3
  56. Flood MP, Roberts G, Mitchell C, et al. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma. *Asia Pac J Clin Oncol*. Published online 2023. doi:10.1111/ajco.13949
  57. Turner KM, Hanna NN, Zhu Y, et al. Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer. *Ann Surg Oncol*. 2013;20(4):1068-1073. doi:10.1245/s10434-012-2789-1
  58. Mercier F, Dagbert F, Pocard M, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *BJS Open*. 2019;3(2):195-202. doi:10.1002/bjs.5.97
  59. Ung L, Chua TC, Morris DL. The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre. *J Cancer Res Clin Oncol*. 2014;140(6):1037-1045. doi:10.1007/s00432-014-1633-3
  60. Grotz TE, Overman MJ, Eng C, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. *Ann Surg Oncol*. 2017;24(9):2646-2654. doi:10.1245/s10434-017-5938-8
  61. Spiliotis J, Kopanakis N, Efstathiou E, et al. Perioperative systemic chemotherapy for peritoneal mucinous appendiceal carcinomas treated with cytoreductive surgery & HIPEC. *J BUON*. 2017;22(3):783-789.
  62. Hanna DN, Macfie R, Ghani MO, et al. Association of Systemic Chemotherapy Approaches With Outcomes in Appendiceal Peritoneal Metastases. *J Surg Res*. 2023;284:94-100. doi:10.1016/j.jss.2022.10.085
  63. Levine EA, Blazer DG, Kim MK, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. *J Am Coll Surg*. 2012;214(4):599-606. doi:10.1016/j.jamcollsurg.2011.12.028
  64. Ang CSP, Shen JP, Hardy-Abeloos CJ, et al. Genomic Landscape of Appendiceal Neoplasms. *JCO Precis Oncol*. 2018;(2):1-18. doi:10.1200/PO.17.00302
  65. Foote MB, Walch H, Chatila W, et al. Molecular Classification of Appendiceal Adenocarcinoma. *J Clin Oncol*. 2022;41:1553-1564. doi:10.1200/JCO.22
  66. Alakus H, Babicky ML, Ghosh P, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. *Genome Med*. 2014;6(5). doi:10.1186/gm559



67. Raghav K, Shen JP, Jácome AA, et al. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. *Br J Cancer*. 2020;123(8):1262-1270. doi:10.1038/s41416-020-1015-3
68. Shen JP, Yousef AM, Zeineddine FA, et al. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma. *JAMA Netw Open*. 2023;6(6):e2316161. doi:10.1001/jamanetworkopen.2023.16161
69. Shaib WL, Martin LK, Choi M, et al. Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. *Oncologist*. 2015;20(8):907-914. doi:10.1634/theoncologist.2014-0294
70. Lu P, Fields AC, Meyerhardt JA, et al. Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. *J Surg Oncol*. 2019;120(3):446-451. doi:10.1002/jso.25599
71. Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. *Cancer*. 2016;122(2):213-221. doi:https://doi.org/10.1002/cncr.29744
72. Turner KM, Morris MC, Delman AM, et al. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study. *Journal of Gastrointestinal Surgery*. 2022;26(12):2569-2578. doi:10.1007/s11605-022-05489-5
73. Strach MC, Chakrabarty B, Nagaraju RT, et al. Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma. *ESMO Open*. 2023;8(5):101619. doi:10.1016/j.esmoop.2023.101619
74. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2015;22(5):1716-1721. doi:10.1245/s10434-014-3985-y
75. Garach NR, Kusamura S, Guaglio M, Bartolini V, Deraco M, Baratti D. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *European Journal of Surgical Oncology*. 2021;47(5):1132-1139. doi:10.1016/j.ejso.2020.08.017
76. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: A single-institution experience. *Cancer*. 2010;116(2):316-322. doi:10.1002/cncr.24715
77. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. *Annals of Oncology*. 2012;23(3):652-658. doi:10.1093/annonc/mdr279
78. Kuijpers AM, Mehta AM, Boot H, et al. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Annals of Oncology*. 2014;25(4):864-869. doi:10.1093/annonc/mdu031

79. Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. *Oncologist*. 2014;19(8):845-850. doi:10.1634/theoncologist.2014-0106
80. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. *Cancer*. 2010;116(2):316-322. doi:10.1002/cncr.24715
81. Tejani MA, ter Veer A, Milne D, et al. Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. *Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw*. 2014;12(8):1123-1130. doi:10.6004/jnccn.2014.0109
82. Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dubé P. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. *Can J Surg*. 2009;52(2):135-141.
83. Mercier F, Dagbert F, Pocard M, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *BJS Open*. 2019;3(2):195-202. doi:10.1002/bjs.5.97
84. Beal EW, Srinivas S, Shen C, et al. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative. *Ann Surg Oncol*. 2023;30(3):1840-1849. doi:10.1245/s10434-022-12753-0
85. Morgan RB, Yan A, Dhiman A, et al. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. *J Gastrointest Surg*. 2022;26(12):2591-2594. doi:10.1007/s11605-022-05423-9
86. Strach MC, Sutherland S, Horvath LG, Mahon K. The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. *Ther Adv Med Oncol*. 2022;14. doi:10.1177/17588359221112478
87. Choe JH, Overman MJ, Fournier KF, et al. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. *Ann Surg Oncol*. 2015;22(8):2578-2584. doi:10.1245/s10434-014-4335-9
88. Raghav KPS, Shetty A V., Kazmi SMA, et al. Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. *Oncologist*. 2013;18(12):1270-1277. doi:10.1634/theoncologist.2013-0186
89. Holowatyj AN, Washington MK, Tavtigian S V., Eng C, Horton C. Inherited Cancer Susceptibility Gene Sequence Variations among Patients with Appendix Cancer. *JAMA Oncol*. 2023;9(1):95-101. doi:10.1001/jamaoncol.2022.5425
90. Foote MB, Walch H, Kemel Y, et al. The Impact of Germline Alterations in Appendiceal Adenocarcinoma. *Clin Cancer Res*. 2023;29(14):2631-2637. doi:10.1158/1078-0432.CCR-22-3956
91. Network NCC. NCCN Guidelines Colon Cancer Version 4. Published November 16, 2023. Accessed January 8, 2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf)
92. Hornstein NJ, Zeineddine MA, Gunes BB, et al. Efficacy and safety of PD-L1 (atezolizumab) and VEGF (bevacizumab) inhibition in appendiceal adenocarcinoma (AA). *Cancer Research Communication*. Accepted.
93. Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for

- Peritoneal Surface Malignancy: Experience with 501 Procedures. *J Am Coll Surg*. 2007;204(5):943-953. doi:10.1016/j.jamcollsurg.2006.12.048
94. Marcotte E, Sideris L, Drolet P, et al. Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin for Peritoneal Carcinomatosis Arising from Appendix: Preliminary Results of a Survival Analysis. *Ann Surg Oncol*. 2008;15(10):2701-2708. doi:10.1245/s10434-008-0073-1
95. Marcotte E, Dubé P, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. *World J Surg Oncol*. 2014;12(1):332. doi:10.1186/1477-7819-12-332
96. Chua TC, Al-Alem I, Saxena A, Liauw W, Morris DL. Surgical Cytoreduction and Survival in Appendiceal Cancer Peritoneal Carcinomatosis: An Evaluation of 46 Consecutive Patients. *Ann Surg Oncol*. 2011;18(6):1540-1546. doi:10.1245/s10434-011-1714-3
97. Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative Findings, Early Complications, and Long-Term Survival in 456 Patients With Pseudomyxoma Peritonei Syndrome of Appendiceal Origin. *Dis Colon Rectum*. 2011;54(3):293-299. doi:10.1007/DCR.0b013e318202f026
98. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to “Pseudomyxoma Peritonei.” *Am J Surg Pathol*. 1995;19(12):1390-1408. doi:10.1097/00000478-199512000-00006
99. Levine EA, Votanopoulos KI, Shen P, et al. A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. *J Am Coll Surg*. 2018;226(4):434-443. doi:10.1016/j.jamcollsurg.2017.12.027
100. Austin F, Mavanur A, Sathaiiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. *Ann Surg Oncol*. 2012;19(5):1386-1393. doi:10.1245/s10434-012-2241-6
101. Chua TC, Yan TD, Smigielski ME, et al. Long-Term Survival in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: 10 Years of Experience from a Single Institution. *Ann Surg Oncol*. 2009;16(7):1903-1911. doi:10.1245/s10434-009-0341-8
102. Gusani NJ, Cho SW, Colovos C, et al. Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center. *Ann Surg Oncol*. 2008;15(3):754-763. doi:10.1245/s10434-007-9701-4
103. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg*. 2007;245(1):104-109. doi:10.1097/01.sla.0000231705.40081.1a
104. Sugarbaker PH, Chang D. Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy. *Ann Surg Oncol*. 1999;6(8):727-731. doi:10.1007/s10434-999-0727-7
105. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with

- peritoneal mucinous carcinomatosis. *Cancer*. 2001;92(1):85-91. doi:10.1002/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R
106. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FAN. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. *British Journal of Surgery*. 2002;88(3):458-463. doi:10.1046/j.1365-2168.2001.01701.x
  107. van Ruth S, Acherman YIZ, van de Vijver MJ, Hart AAM, Verwaal VJ, Zoetmulder FAN. Pseudomyxoma peritonei: a review of 62 cases. *European Journal of Surgical Oncology (EJSO)*. 2003;29(8):682-688. doi:10.1016/S0748-7983(03)00149-5
  108. Gerner Z, Schmidt U, Dahlke MH, Schlitt HJ, Klempnauer J, Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. *Int J Colorectal Dis*. 2005;20(2):155-160. doi:10.1007/s00384-004-0648-7
  109. Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. *British Journal of Surgery*. 2005;93(1):100-104. doi:10.1002/bjs.5210
  110. Stewart JH, Shen P, Russell GB, et al. Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. *Ann Surg Oncol*. 2006;13(5):624-634. doi:10.1007/s10434-006-9708-2
  111. Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P, Schlitt HJ. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. *BMC Cancer*. 2014;14:807. doi:10.1186/1471-2407-14-807
  112. Elias D, Goere D, Blot F, et al. Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Complete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients. *Ann Surg Oncol*. 2007;14(6):1818-1824. doi:10.1245/s10434-007-9348-1
  113. Elias D, Glehen O, Pocard M, et al. A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix. *Ann Surg*. 2010;251(5):896-901. doi:10.1097/SLA.0b013e3181d9765d
  114. Cotte E, Passot G, Tod M, et al. Closed Abdomen Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Mitomycin C: a Phase I Study. *Ann Surg Oncol*. 2011;18(9):2599-2603. doi:10.1245/s10434-011-1651-1
  115. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. *Cancer*. 2006;106(5):1144-1153. doi:10.1002/cncr.21708
  116. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei. *Ann Surg Oncol*. 2004;11(4):393-398. doi:10.1245/ASO.2004.07.002
  117. Somashekhar S, Abba J, Sgarbura O, et al. Assessment of Treatment Response after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Appendiceal Peritoneal Metastases. *Cancers (Basel)*. 2022;14(20):4998. doi:10.3390/cancers14204998

118. Gockel I, Jansen-Winkel B, Haase L, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. *Tumori*. 2020;106(1):70-78. doi:10.1177/0300891619868013
119. Leiting JL, Day CN, Harmsen WS, et al. The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. *Int J Hyperthermia*. 2020;37(1):1182-1188. doi:10.1080/02656736.2020.1819571
120. Wagner PL, Jones D, Aronova A, et al. Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis. *Dis Colon Rectum*. 2012;55(4):407-415. doi:10.1097/DCR.0b013e3182468330
121. Nash GM, Garcia-Aguilar J, Paty P, et al. Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial. *Journal of Clinical Oncology*. 2023;41(4\_suppl):160-160. doi:10.1200/JCO.2023.41.4\_suppl.160
122. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. *Histopathology*. 2020;76(2):182-188. doi:10.1111/his.13975
123. WHO Classification of Tumours Editorial Board, ed. Tumours of the appendix. In: *WHO Classification of Tumours: Digestive System Tumours*. Vol 1. 5th ed. International Agency for Research on Cancer; 2019.
124. Ahadi M, Sokolova A, Brown I, Chou A, Gill AJ. The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. *Pathology*. 2021;53(4):454-461. doi:10.1016/j.pathol.2020.10.010
125. Chua TC, Chong CH, Liauw W, Zhao J, Morris DL. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. *Ann Surg*. 2012;256(2):342-349. doi:10.1097/SLA.0b013e3182602ad2
126. Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2007;14(8):2300-2308. doi:10.1245/s10434-007-9393-9
127. van Ruth S, Hart AAM, Bonfrer JMG, Verwaal VJ, Zoetmulder FAN. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2002;9(10):961-967. doi:10.1007/BF02574513
128. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. *J Surg Oncol*. 2004;87(4):162-166. doi:10.1002/jso.20107
129. Marotta B, Chaudhry S, McNaught A, et al. Predicting underlying neoplasms in appendiceal mucocoeles at CT: Focal versus diffuse luminal dilatation. *American Journal of Roentgenology*. 2019;213(2):343-348. doi:10.2214/AJR.18.20562
130. Sagebiel TL, Mohamed A, Matamoros A, et al. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal

- Epithelial Neoplasm. *Ann Surg Oncol*. 2017;24(12):3667-3672. doi:10.1245/s10434-017-6052-7
131. Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the Appendix Is Rarely Detected by Colonoscopy. *Journal of Gastrointestinal Surgery*. 2009;13(4):668-675. doi:10.1007/s11605-008-0774-6
  132. Smeenk RM, van Velthuysen MLF, Verwaal VJ, Zoetmulder FAN. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. *Eur J Surg Oncol*. 2008;34(2):196-201. doi:10.1016/j.ejso.2007.04.002
  133. González-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. *British Journal of Surgery*. 2004;91(3):304-311. doi:10.1002/bjs.4393
  134. Polydorides AD, Wen X. Clinicopathologic parameters and outcomes of mucinous neoplasms confined to the appendix: a benign entity with excellent prognosis. *Modern Pathology*. 2022;35(11):1732-1739. doi:10.1038/s41379-022-01114-7
  135. Ibrahim E, Akrmah M, Ligato S. Does a Positive Appendiceal Resection Margin in Low-Grade Appendiceal Mucinous Neoplasms, Warrant Additional Surgery? Our Institution Experience and Literature Review. *Ann Surg Oncol*. 2023;30(12):7189-7195. doi:10.1245/s10434-023-13930-5
  136. Gupta AR, Brajcich BC, Yang AD, Bentrem DJ, Merkow RP. Necessity of posttreatment surveillance for low-grade appendiceal mucinous neoplasms. *J Surg Oncol*. 2021;124(7):1115-1120. doi:10.1002/jso.26621
  137. Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J. Prognostic Significance of Localized Extra-appendiceal Mucin Deposition in Appendiceal Mucinous Neoplasms. *American Journal of Surgical Pathology*. 2009;33(2):248-255. doi:10.1097/PAS.0b013e31817ec31e
  138. Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. *Modern Pathology*. 2015;28:S67-S79. doi:10.1038/modpathol.2014.129
  139. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal Mucinous Neoplasms. *American Journal of Surgical Pathology*. 2009;33(10):1425-1439. doi:10.1097/PAS.0b013e3181af6067
  140. Gamboa AC, Zaidi MY, Lee RM, et al. Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. *Ann Surg Oncol*. 2020;27(1):134-146. doi:10.1245/s10434-019-07526-1
  141. Feferman Y, Solomon D, Bhagwandin S, et al. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. *Ann Surg Oncol*. 2019;26(2):482-489. doi:10.1245/s10434-018-6860-4
  142. Govaerts K, Chandrakumaran K, Carr NJ, et al. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei. *European Journal of Surgical Oncology*. 2018;44(9):1371-1377. doi:10.1016/j.ejso.2018.06.023
  143. Murage NW, Ahmed NM, Underwood TJ, Walters ZS, Breininger SP. The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal

- mucinous neoplasms: a systematic review. *Cancer and Metastasis Reviews*. 2023;42(1):335-359. doi:10.1007/s10555-023-10088-0
144. Moaven O, Su J, Jin G, et al. Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. *Ann Surg Oncol*. 2020;27(13):5016-5023. doi:10.1245/s10434-020-08841-8
  145. Foote MB, Walch H, Kemel Y, et al. The Impact of Germline Alterations in Appendiceal Adenocarcinoma. *Clinical Cancer Research*. 2023;29(14):2631-2637. doi:10.1158/1078-0432.CCR-22-3956
  146. Zeineddine MA, Zeineddine FA, Yousef AMG, et al. Utility of circulating tumor DNA (ctDNA) in the management of appendiceal adenocarcinoma (AA). *Journal of Clinical Oncology*. 2023;41(4\_suppl):226-226. doi:10.1200/JCO.2023.41.4\_suppl.226
  147. Lopez-Ramirez F, Sardi A, King MC, et al. Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix. *Ann Surg Oncol*. Published online December 28, 2023. doi:10.1245/s10434-023-14683-x
  148. Marks VA, Kerekes D, Butensky S, et al. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. *BMC Gastroenterol*. 2023;23(1). doi:10.1186/s12876-023-03019-4
  149. Straker RJ, Grinberg SZ, Sharon CE, et al. Pathologic Factors Associated with Low Risk of Lymph Node Metastasis in Nonmucinous Adenocarcinoma of the Appendix. *Ann Surg Oncol*. 2022;29(4):2334-2343. doi:10.1245/s10434-021-11213-5
  150. Shaib WL, Assi R, Shamseddine A, et al. Appendiceal Mucinous Neoplasms: Diagnosis and Management. *Oncologist*. 2017;22(9):1107-1116. doi:10.1634/theoncologist.2017-0081
  151. Beal EW, Chen JC, Kim A, et al. Is Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy Still Indicated in Patients With Extraperitoneal Disease? *Journal of Surgical Research*. 2022;277:269-278. doi:10.1016/j.jss.2022.04.007
  152. Govaerts K, Lurvink RJ, De Hingh IHJT, et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. *European Journal of Surgical Oncology*. 2021;47(1):11-35. doi:10.1016/j.ejso.2020.02.012
  153. Glasgow SC, Gaertner W, Stewart D, et al. The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. *Dis Colon Rectum*. 2019;62(12):1425-1438. doi:10.1097/DCR.0000000000001530
  154. Vaira M, Robella M, Guaglio M, et al. Diagnostic and Therapeutic Algorithm for Appendiceal Tumors and Pseudomyxoma Peritonei: A Consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology (SICO). *Cancers (Basel)*. 2023;15(3):728. doi:10.3390/cancers15030728